Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04919512
Title A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

bladder urothelial carcinoma

Therapies

Cetrelimab + TAR-200

Cetrelimab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | BEL


No variant requirements are available.